Nanoparticle Platforms in Clinical and Preclinical Development for Intranasal CNS Delivery

Nanoparticle nose-to-brain delivery for neurological indications uses lipid-based, polymeric, protein-based, and inorganic carriers to protect drugs and support transport through the olfactory and trigeminal pathways. Lipid and polymeric platforms lead in manufacturing maturity and regulatory familiarity, while protein-based and inorganic systems offer precision with greater translational complexity. The central distinction is between demonstrated preclinical delivery and clinical readiness, which still depends on human safety, scalable production, and regulatory progress.

Why the blood-brain barrier makes CNS drug delivery structurally different from other therapeutic fields

The blood-brain barrier is an anatomical constraint. Endothelial cells and tight junctions, supported by astrocytes, pericytes, and neurons, form a selective interface that restricts passage into the brain. It blocks nearly all macromolecules and the vast majority of small molecules. A drug’s activity in vitro therefore does not establish that it can reach its target in vivo. CNS development also faces biological, technical, clinical, and regulatory challenges, but access comes before pharmacological effect.

A drug taken by mouth may reach other organs at potentially toxic doses while too little reaches the brain to treat it. Intraparenchymal, intracerebroventricular, and intrathecal injections provide CNS access, but their invasiveness limits their suitability for chronic use.

How do the olfactory and trigeminal pathways enable nose-to-brain drug delivery?

The nasal cavity has a direct anatomical connection to the CNS through the olfactory and trigeminal pathways. Drugs deposited in the upper nasal cavity can travel along olfactory nerve axons into the olfactory bulb and then into deeper brain structures. The trigeminal pathway provides parallel access to the brainstem and thalamus. Lymphatic drainage is a third, slower way for drugs to build up in the CNS, separate from direct neural transport. These connections make the nose more than a convenient administration site.

Direct transport can keep a drug from entering systemic circulation. It can also avoid gastrointestinal and hepatic first-pass metabolism, reduce accumulation in non-targeted organs, and shorten the time needed to reach the brain. Those advantages explain the interest in intranasal delivery, but they do not establish how much of any particular formulation reaches its intended CNS target. Approved nasal formulations for migraine, epilepsy, depression, and opioid overdose demonstrate regulatory precedent for nasal administration.

Why unformulated drugs fail the nose-to-brain route and what nanocarriers are engineered to fix

An anatomical shortcut is not an unprotected passage. Nasal enzymes degrade peptides, while mucociliary clearance moves deposited material toward the throat within minutes. Continuous mucus turnover further limits residence time, including for molecules that adhere to the mucosa. In practice, a drug must not only be able to enter a neural pathway, but remain intact and available long enough to do so.

Encapsulation shields the cargo from enzymatic attack, surface engineering prolongs mucosal contact, and controlled release extends drug availability within the absorption window. Carriers can also improve solubility and bioavailability, with surface functionalization offering a means of targeting particular brain regions. GLP-1 peptides illustrate the stakes because their vulnerability to nasal enzymes makes protective formulation a prerequisite for the proposed route.

GLP-1's expanding neurological indications and why brain-targeted delivery matters beyond metabolic disease

GLP-1 receptors are found on specific groups of neurons throughout the brain, which gives them a way to act beyond peripheral metabolism. Nørgaard et al. 2022 pooled three major cardiovascular outcome trials and found that participants with type 2 diabetes who received liraglutide or semaglutide had a much lower hazard of a later dementia diagnosis than those who received placebo. A trial of roughly 9,000 participants with type 2 diabetes and cardiovascular risk also associated dulaglutide with reduced risk of cognitive decline, another signal for neurological indications that remain unapproved.

The potential extends beyond cognition into reward and neuronal resilience. Associations with reduced risk of seizures and addiction to alcohol, cannabis, stimulants, and opioids accompany mechanisms involving impulse control, reward, and mesolimbic dopamine function. GLP-1 receptor activation also attenuates oxidative stress and acts on mitochondrial dysfunction and neuronal death pathways. Together, these findings motivate research into dementia, Parkinson's, and substance use disorder. They do not establish equivalent benefit across those conditions.

Delivery researchers must now ask whether the amount of drug that reaches the brain limits those effects. Subcutaneous delivery requires access across the BBB to reach neuronal targets, whereas direct intranasal transport could bypass that requirement. Close to one in eight Americans have taken GLP-1s for metabolic indications, but neurological use would pose a different targeting problem. A brain-directed formulation could be better suited to that problem, although superiority over injection remains to be demonstrated.

Why the injectable delivery paradigm produces structural dropout that formulation can solve

Prime Therapeutics, 2025 reported that only a small minority of patients remained on GLP-1 therapy after three years. A Danish semaglutide study presented at EASD 2025 followed 77,310 first-time users and found that more than half stopped within one year. Attrition was already substantial at three months and continued steeply through nine months. Abandonment before the first fill adds a separate loss before treatment even begins.

Cost and insurance account for the largest share of discontinuation reasons, so formulation cannot solve the entire persistence problem. Gastrointestinal side effects are still the leading reason for stopping that a formulation could address, with roughly half of users reporting nausea and a third reporting diarrhea. Needles add another burden, especially during chronic treatment for people who already have diabetes-related injection fatigue. These are predictable treatment burdens. A brain-targeted nasal formulation could reduce peripheral exposure and remove the need for injections, but the route alone gives no assurance that gastrointestinal symptoms would disappear.

Lipid-based nanocarriers as the translational frontrunner class for nose-to-brain delivery

Lipid-based systems have the broadest translational range among the platform classes. Because they are made of materials like those in membranes, they support biological compatibility, and experience in making them offers a starting point for production at scale. Solid lipid nanoparticles and nanostructured lipid carriers use tailored lipid compositions to control drug loading and release. Liposomes accommodate both hydrophilic and lipophilic drugs and permit surface modification for mucoadhesion or active targeting. These systems differ in drug-class fit.

Nanoemulsions offer an approach to poor solubility, limited bioavailability, slow onset, and enzymatic degradation. Niosomes use non-ionic surfactant vesicles as a lower-cost alternative and have shown improved intranasal efficacy at reduced doses with fewer systemic side effects. Lipid encapsulation is also the most studied approach for the proposed intranasal delivery of GLP-1 peptides because it directly addresses enzymatic vulnerability. However, established lipid products do not validate a new nasal CNS formulation.

The class also reaches into gene-level intervention. Scientists at the Icahn School of Medicine at Mount Sinai developed MK16 BLNPs in February 2025 for mRNA transport through caveolae- and γ-secretase-mediated transcytosis across the BBB. These particles achieved significantly higher delivery efficiency than existing FDA-approved lipid nanoparticles. That finding broadens the lipid platform’s cargo potential through BBB crossing. It belongs to the wider technology landscape.

Polymeric nanoparticles and the PLGA advantage in regulatory familiarity and mucoadhesive precision

PLGA, or poly(lactic-co-glycolic acid), offers a different kind of head start. This biocompatible, biodegradable polymer is already used in FDA-approved pharmaceutical products and medical devices. Familiarity with the material reduces uncertainty relative to an entirely novel carrier, although it does not confer approval on a new nanoparticle formulation. Its value is practical as well as biological. Tunable degradation permits release profiles suited to the pharmacokinetic requirements of chronic neurological treatment.

Dogra et al., 2025 demonstrated high mucoadhesive activity and significantly greater intranasal absorption with mefenamic acid-loaded PLGA nanoparticles than with a free drug suspension in a preclinical Alzheimer's disease application. Longer contact directly counters loss through mucociliary clearance. Surface coatings provide further control, with chitosan enhancing mucoadhesion and opening tight junctions, PEG reducing protein adsorption and extending circulation, and targeting ligands supporting specific brain-region accumulation. Each modification serves a different transport objective. The ability to encapsulate peptide cargoes also makes PLGA a credible candidate for intranasal GLP-1 development.

Protein-based and inorganic nanocarriers offer precision targeting at the cost of translational complexity

Protein-based carriers use biological recognition as well as passive diffusion. Albumin nanoparticles, exosomes, and protein cages offer surfaces that can interact with receptor-mediated transport mechanisms. Engineered surface proteins can mimic ligands recognized by nasal epithelial receptors, supporting active uptake. Exosomes add inherent biocompatibility and natural brain-homing properties. Yet their cell-derived origin brings unresolved challenges in manufacturing scale and batch consistency.

Gold nanoparticles, silica nanoparticles, and carbon-based structures provide stable, tunable surface chemistry, sometimes with diagnostic imaging capability. Researchers at King's College London published a July 2025 study in Small demonstrating nose-to-brain delivery of acyl-ghrelin peptide gold nanoconjugates for neurodegenerative disease treatment. This preclinical result connects endogenous peptide conjugation with olfactory-route delivery. Long-term brain accumulation and incompletely characterized clearance nevertheless remain major safety concerns for non-biodegradable inorganic carriers.

These platforms remain research frontiers rather than near-term substitutes for mature manufacturing systems. Protein-based production requires biological process control, while inorganic production requires precise physicochemical control. That complexity may be justified when spatial targeting or imaging-linked delivery matters most, including for brain tumors and defined neurodegenerative lesions.

The 2025 bioadhesion advance that addresses the route's principal kinetic barrier directly

Surviving nasal clearance requires more than carrier composition alone. Jia et al., Acta Biomaterialia, 2025 demonstrated enhanced nasal-to-brain delivery using multivalent bioadhesive nanoparticle clusters for protection against cerebral ischemic reperfusion injury. Multiple low-affinity interactions with mucin glycoproteins combine into high-avidity binding, resisting clearance more effectively than monovalent adhesion. The advance targets residence time.

A particle held tightly at the mucosa may resist onward movement, while one optimized for rapid uptake may disappear before enough drug is absorbed. How much attachment supports delivery, and when does it obstruct it? Cluster architectures offer one way to navigate that tension across lipid, polymeric, and protein-based cores. This cross-class design dimension shows a field moving from selecting materials toward coordinating sequential transport steps.

Where the field actually sits on the bench-to-clinic spectrum and what the translation gap means in practice

Nanotechnology-enabled intranasal CNS delivery remains predominantly preclinical. Approved nasal treatments for migraine and epilepsy establish a viable administration route, but they are not nanocarrier-specific clinical validation. These platforms have shown strong signs of efficacy in vitro and in animals, but none has yet led to approved CNS products. That distinction limits what can be claimed today. Successful delivery in an animal model does not resolve repeated-exposure safety in the human nose and brain.

Long-term effects on the nasal mucosa and olfactory epithelium are not fully characterized in humans. Lipid and PLGA systems have more mature production processes, while protein-based and inorganic platforms face steeper scale-up challenges. Nanocarrier-specific regulatory guidance for intranasal CNS delivery is also less established than pathways for comparable injectable biologics. Each program must account for its own cargo, surface chemistry, and pattern of exposure.

Optimization must work across two distinct biological environments. Artificial intelligence-driven formulation design is emerging as a way to explore combinations that manual iteration cannot assess quickly, but it is not a substitute for human evidence. The GLP-1 findings also require proportionate expectations, with neurological risk reductions roughly ten to twenty percent for most outcomes. Those signals can be meaningful without establishing transformative benefit. Whether more reliable CNS exposure improves them remains an experimental question.

What the platform landscape collectively reveals about the path from preclinical promise to clinical delivery

The strongest development strategy is not tied to one carrier material. Regulatory familiarity and manufacturing maturity favor lipid and polymeric systems, while targeting demands can justify protein-based or inorganic components in hybrid approaches. Mucoadhesive architecture offers another way to control how those systems behave at the nasal surface. Decades of foundational nanoparticle intellectual property support this work. The engineering built up over time gives this work credibility, while a new route alone is no guarantee of a better medicine.

GLP-1 peptides provide a demanding test of that capability because biological signals, peptide instability, and treatment persistence converge in one application. For patients with dementia or substance use disorders, and for those who have abandoned injections, usable delivery is also an access question. The next requirements are human safety data for repeated exposure, manufacturing protocols validated for these CNS applications, and regulatory dialogue. Progress on those requirements could support other peptide therapeutics and gene editing payloads. The opportunity is broader than a single product, but clinical confidence must be earned formulation by formulation.